Clear Cell Renal Cell Cancer (ccRCC)
7
3
4
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
14%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors